For its handful of major annual decisions, Eli Lilly's leadership team has a rule to never make a final call in the initial meeting. This process intentionally builds in time for reflection, debate, and persuasion.

Effective leadership in an innovation-driven company isn't about being 'tough' but 'demanding' of high standards. The Novonesis CEO couples this with an explicit acceptance of failure as an inherent part of R&D, stressing the need to 'fail fast' and learn from it.

Instead of fearing failure, Ridge institutionalizes it by allocating a $1M annual budget specifically for testing new product expansions. This removes pressure from any single launch, encourages aggressive experimentation, and has led to eight-figure successes alongside predictable flops like watches.

Afeyan advises against making breakthrough innovation everyone's responsibility, as it's unsustainable and disruptive to daily jobs. Instead, companies should create a separate group with different motivations, composition, and rewards, focused solely on discontinuous leaps.

Responding to Wall Street pressure to de-risk, large pharmaceutical firms cut internal early-stage research. This led to an exodus of talent and the rise of contract research organizations (CROs), creating an infrastructure that, like cloud computing for tech, lowered the barrier for new biotech startups.

Unconventional AI operates as a "practical research lab" by explicitly deferring manufacturing constraints during initial innovation. The focus is purely on establishing "existence proofs" for new ideas, preventing premature optimization from killing potentially transformative but difficult-to-build concepts.

PepsiCo's R&D head created global "flavor banks" to catalog both successful and failed experiments from around the world. This system allowed disparate teams to build on shared institutional knowledge instead of starting from scratch. It fostered productive internal competition and dramatically increased the speed and success rate of new product development.

Rewarding successful outcomes incentivizes employees to choose less risky, less innovative projects they know they can complete. To foster true moonshots, Alphabet's X rewards behaviors like humility and curiosity, trusting that these habits are the leading indicators of long-term breakthroughs.

To avoid the pitfalls of scale in R&D, Eli Lilly operates small, focused labs of 300-400 people. These 'internal biotechs' have mission focus and autonomy, while leveraging the parent company's scale for clinical trials and distribution.